Human Papilloma Virus Vaccine – Epidemiology – Mature Markets Data
Clarivate Epidemiology’s coverage of the human papillomavirus (HPV) vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the eligible population recommended to receive the HPV vaccine for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s HPV vaccine forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the HPV vaccine-eligible population over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following HPV vaccine patient populations:
- The population eligible for the HPV vaccine.
- The population newly eligible for the HPV vaccine.
Note: Coverage may vary by country.
